Coronary Artery Disease, Hemolysis, Renal Failure
Conditions
Brief summary
The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysulfone membranes and polyamide membranes) on antiplatelet efficacy. A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after two times of haemodialysis.
Interventions
DEVICEClopidogrel group;Ticagrelor group
A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* diagnosis of coronary heart disease including stable angina, unstable angina, acute myocardial infarction * taking dual antiplatelet drugs (clopidogrel 75mg qd + aspirin 100mg qd or ticagrelor 90 mg,bid + aspirin 100 mg,qd) at least 5 days * haemodialysis patients * sign informed consent
Exclusion criteria
* platelet count\>450 × 10 9 /L or \<100 × 10 9 /L * using IIb / IIIa inhibitor drugs within 10days * taking nonsteroidal anti-inflammatory drugs other than aspirin * hemorrhagic disease * allergic to aspirin, ticagrelor or clopidogrel * other factors may affect the results of this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| using light transmittance aggregometer to detect whether haemodialysis can affect the efficacy of antiplatelet agents | collecting blood within 10 miuntes before and after haemodialysis;detecting them within 2 hours | intravenous blood collection with anticoagulant tube before and after haemodialysis respectively ；using light transmittance aggregometer to detect adenosine diphosphate induced platelet aggregation rate and arachidonic acid induced platelet aggregation rate within two hours after blood collection;;compare the outcome of light transmittance aggregometer with VerifyNow |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| using VerifyNow to detect whether haemodialysis can affect the efficacy of antiplatelet agents | collecting blood within 10 miuntes before and after haemodialysis;detecting them within 2 hours | intravenous blood collection with VeryfiNow to detect the platelet reaction unit before and after haemodialysis respectively |
Countries
China
Outcome results
None listed